Financial Performance - The company's revenue for Q1 2025 was ¥98,512,592.70, representing a 1.65% increase compared to ¥96,914,552.27 in the same period last year[5]. - Net profit attributable to shareholders decreased by 9.81% to ¥4,876,118.66 from ¥5,406,482.66 year-on-year[5]. - The net profit after deducting non-recurring gains and losses was -¥520,711.29, a decline of 123.38% from ¥2,227,226.37 in the same period last year[5]. - The basic and diluted earnings per share were both ¥0.0827, down 9.81% from ¥0.0917 in the same period last year[5]. - Net profit for the current period was ¥4,876,118.66, representing a 16.63% increase from ¥4,180,945.30 in the previous period[28]. - The company reported a comprehensive income total of ¥6,999,527.89, compared to ¥3,611,210.76 in the previous period, indicating a significant increase[29]. Cash Flow and Assets - The net cash flow from operating activities surged by 180.78%, reaching ¥44,901,709.05 compared to ¥15,992,014.05 in the previous year[5]. - Cash and cash equivalents rose to ¥589,291,668.04, up from ¥407,228,869.75, representing a significant increase of about 44.66%[23]. - The total current assets increased to ¥937,961,788.83 from ¥922,876,080.02, reflecting a growth of approximately 1.17%[23]. - The total assets amounted to ¥1,845,252,618.05, compared to ¥1,794,790,236.24, indicating an increase of approximately 2.81%[24]. - The total liabilities increased to ¥651,131,505.41 from ¥602,456,107.11, indicating a rise in financial obligations[25]. - The total equity attributable to shareholders reached ¥1,194,121,112.64, slightly up from ¥1,187,121,584.75 in the previous period[25]. Shareholder Activities - The company approved a share repurchase plan with a total amount between RMB 30 million and RMB 60 million, targeting to buy back 600,000 to 1,200,000 shares, representing 1.02% to 2.04% of the total share capital[13]. - As of February 7, 2025, the company completed the repurchase of 1,427,400 shares at a total cost of RMB 57,641,335.95, accounting for 2.42% of the current total share capital[14]. - The highest share repurchase price was RMB 42.80 per share, while the lowest was RMB 32.71 per share during the buyback period[14]. - The share repurchase period is set from February 8, 2024, to February 7, 2025, following the board's approval[13]. Investments and Acquisitions - The company plans to acquire CRRT filter business assets from BELLCO S.R.L. for an estimated price of €11.99 million, with the transaction yet to be completed[15]. - The company agreed to invest RMB 60 million in a related party, acquiring a 20.87% stake in Ningbo Tianhuiyi Enterprise Management Co., Ltd[16]. - The company and its subsidiary completed the acquisition of CRRT business from Nikkiso Co., Ltd for €43.54 million in February 2025[16]. Research and Development - The increase in sales personnel and R&D staff contributed to higher sales and R&D expenses, impacting net profit[8]. - Research and development expenses rose to ¥11,762,426.61, up from ¥10,309,491.39 in the previous period, reflecting a focus on innovation[27]. - The company is actively expanding its product portfolio with ongoing development and registration of various medical devices[19]. - The company is in the process of registering several new medical devices, including a blood purification device and a continuous blood purification pipeline, currently under review[21]. - The company has multiple new products in the pipeline, with expected approvals for various medical devices extending into 2030[20]. Inventory and Operating Costs - The company reported a significant increase in inventory, with current inventory at ¥85,709,970.06, slightly down from ¥86,799,967.45, indicating a stable inventory management strategy[23]. - Total operating costs increased to ¥98,982,139.54, up 5.00% from ¥93,815,124.46 in the previous period[27].
天益医疗(301097) - 2025 Q1 - 季度财报